AXSM
Axsome Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.6% ·
share flow +6.2% ·
net new positions -5.9%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 129 | +8 | 27.56M | $6.74B | +16 | −9 |
| Q1 2026 | 125 | +4 | 27.78M | $4.69B | +9 | −6 |
| Q4 2025 | 120 | +1 | 28.15M | $5.13B | +2 | — |
| Q3 2025 | 19 | 0 | 15.93M | $1.93B | +1 | −2 |
| Q2 2025 | 17 | -1 | 13.98M | $1.46B | — | −1 |
| Q1 2025 | 15 | +3 | 4.41M | $513.88M | +3 | — |
| Q4 2024 | 12 | +1 | 3.90M | $329.80M | +1 | — |
| Q3 2024 | 10 | 0 | 3.50M | $314.34M | — | — |
| Q2 2024 | 10 | — | 4.77M | $384.18M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 3.95M | — | $411.82M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 3.83M | — | $400.33M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 3 | Geode Capital Management ✦ (passive) | 989.45K | +5.8% | $103.30M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 4 | Fidelity (FMR) ✦ | 976.73K | — | $101.96M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 5 | State Street Global Advisors ✦ (passive) | 958.50K | +5.8% | $100.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 725.04K | +3.1% | $75.69M | 0.0% | ▲ Add | 5 | SEC ↗ ×7 |
| 7 | T. Rowe Price ✦ | 612.74K | +1816.2% | $63.97M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Norges Bank ✦ (passive) | 468.33K | +7.0% | $48.89M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 447.00K | +831.2% | $46.66M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 350.97K | +178.1% | $36.64M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 200.76K | -63.3% | $20.96M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Renaissance Technologies ✦ | 138.70K | +3.2% | $14.48M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 127.82K | +119.0% | $13.34M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 14 | Bridgewater Associates ✦ | 107.29K | +150.5% | $11.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 56.72K | -17.4% | $5.92M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 16 | Millennium Management ✦ | 30.62K | -87.0% | $3.20M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 13.62K | -83.8% | $1.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $5.48M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 408 holders, 37.64M shares, $6.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 10.00K sh · $2.09M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology